DS-8201开启了HER2阳性晚期胃癌靶向治疗新篇章  

DS-8201 Opens a New Chapter in Targeted Therapy for HER2-Positive Advanced Gastric Cancer

作　　者：李佳雨 王风华[1] LI Jia-yu;WANG Feng-hua(Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,China)

机构地区：[1]中山大学肿瘤防治中心内科、华南肿瘤学国家重点实验室、肿瘤医学协同创新中心,广州510060

出　　处：《循证医学》2021年第5期273-277,共5页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Shitara K,Bang YJ,Iwasa S,et al.Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer[J].N Engl J Med,2020,382(25):2419-2430.2证据水平1b。3背景大约有15%~20%的晚期胃癌患者存在人表皮生长因子受体2(human epidermal growth factorreceptor 2,HER2)过表达或扩增。

关 键 词：HER2阳性 胃癌 DESTINY-Gastric01 DS-8201 

分 类 号：R735.2[医药卫生—肿瘤]